Synthetic Biologics is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for treating serious infectious diseases. In collaboration with Intrexon, Synthetic Biologics is developing a synthetic DNA-based therapy for treating pulmonary arterial hypertension (PAH). The company is also developing treatments for relapsing-remitting multiple sclerosis, cognitive dysfunction in MS and amyotrophic lateral sclerosis. For more information, visit the company’s Web site at www.syntheticbiologics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: